首页> 外文期刊>American journal of medical genetics, Part A >Novel De Novo Mutations in ZBTB20 in Primrose Syndrome with Congenital Hypothyroidism
【24h】

Novel De Novo Mutations in ZBTB20 in Primrose Syndrome with Congenital Hypothyroidism

机译:在先天性甲状腺功能减退症的月见草综合征中ZBTB20的新型从头突变。

获取原文
获取原文并翻译 | 示例
           

摘要

The cardinal features of Primrose syndrome (MIM 259050) are dysmorphic facial features, macrocephaly, and intellectual disability, as well as large body size, height and weight, and calcified pinnae. A variety of neurological signs and symptoms have been reported including hearing loss, autism, behavioral abormalities, hypotonia, cerebral calcifications, and hypoplasia of the corpus callosum. Recently, heterozygous de novo missense mutations in ZBTB20, coding for a zing finger protein, have been identified in Primrose syndrome patients. We report a boy with intellectual disability carrying two de novo missense mutations in the last exon of ZBTB20 (Ser616Phe and Gly741Arg; both previously unreported). One of them, Ser616Phe, affects an amino acid located in one of the C2H2 zing-fingers involved in DNA-binding and close to other missense mutations already described. Reverse phenotyping showed that this patient presents with classic features of Primrose syndrome (dysmorphic facies, macrocephaly, hearing loss, hypotonia, hypoplasia of the corpus callosum) and, in addition, congenital hypothyroidism. Review of the literature reveals another Primrose syndrome patient with hypothyroidism and thus, this may represent an under recognized component that should be investigated in other patients. (C) 2016 Wiley Periodicals, Inc.
机译:Primrose综合征(MIM 259050)的主要特征是畸形的面部特征,大头畸形和智力残疾,以及较大的体型,身高和体重以及钙化的耳廓。已经报道了多种神经系统症状和体征,包括听力丧失,自闭症,行为异常,肌张力低下,脑钙化和call体发育不全。最近,在报春花综合症患者中已经鉴定出ZBTB20的杂合的从头错义突变,该突变编码Zing Finger蛋白。我们报道了一个智障男孩,他在ZBTB20的最后一个外显子中携带两个从头错义突变(Ser616Phe和Gly741Arg;之前均未报道)。其中之一,Ser616Phe,会影响位于与DNA结合有关的C2H2姜指中的一个氨基酸,并接近已描述的其他错义突变。反向表型表明该患者具有月见草综合征的典型特征(畸形相,大头畸形,听力下降,肌张力低下,call体发育不全),此外,还患有先天性甲状腺功能减退症。文献综述揭示了另一位患有甲状腺功能减退症的樱草花综合征患者,因此,这可能代表了一个未被认可的成分,应在其他患者中进行研究。 (C)2016威利期刊公司

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号